MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.53
+0.90
+6.60%
Closed 16:10 10/21 EDT
OPEN
13.86
PREV CLOSE
13.63
HIGH
14.70
LOW
13.84
VOLUME
584.52K
TURNOVER
--
52 WEEK HIGH
22.82
52 WEEK LOW
11.00
MARKET CAP
1.09B
P/E (TTM)
-11.8913
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FATE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FATE News

  • What Kind Of Shareholder Owns Most Fate Therapeutics, Inc. (NASDAQ:FATE) Stock?
  • Simply Wall St..3d ago
  • Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock?
  • Simply Wall St..3d ago
  • 50 Biggest Movers From Yesterday
  • Benzinga.10/10 09:18
  • Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio
  • Benzinga.10/01 18:48

More

Industry

Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+0.40%

Hot Stocks

Name
Price
%Change

About FATE

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
More

Webull offers Fate Therapeutics Inc (FATE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.